Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial.

Authors

Karen L Furie
Catherine M Viscoli
Mark Gorman, Maine Medical Center
Gary A Ford
Lawrence H Young
Silvio E Inzucchi
Peter D Guarino
Anne M Lovejoy
Robin Conwit
David Tanne
Walter N Kernan

Document Type

Article

Publication Date

1-2018

Institution/Department

Neurology

Journal Title

Journal of neurology, neurosurgery, and psychiatry

MeSH Headings

Cognition, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Ischemic Attack, Transient, Longitudinal Studies, Male, Middle Aged, Risk Factors, Stroke, Thiazolidinediones

Abstract

INTRODUCTION: Patients with cerebrovascular disease are at increased risk for cognitive dysfunction. Modification of vascular risk factors, including insulin resistance, could improve poststroke cognitive function.

METHODS: In the Insulin Resistance Intervention after Stroke (IRIS) trial, patients with a recent ischaemic stroke or transient ischaemic attack (TIA) were randomised to pioglitazone (target 45 mg daily) or placebo. All patients were insulin resistant based on a Homeostasis Model Assessment-Insulin Resistance score >3.0. For this preplanned analysis of cognitive function, we examined the Modified Mini-Mental State Examination (3MS) score (maximum score, 100) during follow-up. Patients were tested at baseline and annually for up to 5 years. Longitudinal mixed model methods were used to compare changes in the 3MS over time.

RESULTS: Of the 3876 IRIS participants, 3398 had a 3MS score at baseline and at least once during follow-up and were included in the analysis. Median 3MS score at baseline was 97 (IQR 93-99). The average overall least squared mean 3MS score increased by 0.27 in the pioglitazone group and by 0.29 in the placebo group (mean difference between treatment groups -0.02; 95% CI -0.33 to 0.28, p=0.88).

CONCLUSIONS: Among insulin-resistant patients with a recent ischaemic stroke or TIA, pioglitazone did not affect cognitive function, as measured by the 3MS, over 5 years.

TRIAL REGISTRATION: ClinicalTrials.gov NCT00091949; Results.

ISSN

1468-330X

First Page

21

Last Page

27

Recommended Citation

Furie, Karen L; Viscoli, Catherine M; Gorman, Mark; Ford, Gary A; Young, Lawrence H; Inzucchi, Silvio E; Guarino, Peter D; Lovejoy, Anne M; Conwit, Robin; Tanne, David; and Kernan, Walter N, "Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial." (2018). MaineHealth Maine Medical Center. 68.
https://knowledgeconnection.mainehealth.org/mmc/68